Roivant Reports $35.1 Million Revenue and $191.6 Million Net Loss
Roivant reported the results for the second quarter ended September 30, 2026. The quarter included the U.S. launch of LISRAYA and progress across several clinical programs; consolidated cash was $4.2 billion.
Roivant reported $35.1 million in revenue and a net loss attributable to the company of $191.6 million for the second quarter ended September 30, 2026. The quarter included the U.S. launch of LISRAYA and progress across several clinical programs. Roivant had $4.2 billion in consolidated cash, cash…